Netherlands-based Corbion posted a double-digit jump in its EBIDTA in H1 2025 as it saw increased margins in both business segments.
For H1 2025, Corbion achieved revenues of EUR 645.6 million (USD 747 million), up 1.3 percent from the EUR 637.1 million (USD 737 million) it posted in the same period of 2024. Its EBITDA, meanwhile, saw a much larger increase, jumping 23.8 percent from EUR 86.1 million (USD 99.6 million) in H1 2024 to EUR 106.6 (USD 123.3 million) in H1 2025.
The company added that its organic growth stood at 29.3 percent, and its operating profit reached EUR 63.5 million (USD 73.5 million), an 89 percent increase from the EUR 33.6 million (USD 38.8 million) it posted in H1 2024.
“We have once again demonstrated the resilience of our businesses with a strong performance in the first half of 2025,” Corbion CEO Olivier Rigaud said in a release. “Our significant progress in our cost-savings program and decline of some key input costs, combined with our focus on operational excellence has led to increased margins in both segments.”
Corbion, which provides solutions for seafood safety and preservation and produces omega-3 ingredients for feed for salmon farms, also produces a number of pharmacological, biomedical, and food products.
The company said its sales increased for both its functional ingredients and solutions segment and its health and nutrition segment. However, most of its growth came from the health and nutrition segment, as between lower prices and currency adjustments its functional ingredients and solutions segment only posted 0.1 percent total growth.
Rigaud said that the segment was experiencing positive momentum, and that for the second half of the year, Corbion expects to increase the volume and mix of natural preservation solutions.
The company said looking forward to the second half of 2025 it is on track to deliver adjusted EBIDTA growth of greater than 25 percent.
“Sales are expected to increase for the full year driven by volume/mix growth in the Food business and Health & Nutrition segment,” the company said. “Pricing is expected to be slightly negative while Adjusted EBITDA margins are expected to increase versus FY 2024.”
